Structure-based de novo design of Eya2 phosphatase inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Hwangseo | - |
dc.contributor.author | Ryu, Seong Eon | - |
dc.contributor.author | Kim, Seung Jun | - |
dc.date.accessioned | 2022-07-16T13:58:38Z | - |
dc.date.available | 2022-07-16T13:58:38Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2012-09 | - |
dc.identifier.issn | 1093-3263 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/164825 | - |
dc.description.abstract | Although Eyes absent protein tyrosine phosphatases proved to be involved in various human cancers by a series of persuasive experimental evidence, only a very few number of small-molecule inhibitors have been reported so far. We have been able to identify 29 novel inhibitors of Eyes absent homologue 2 (Eya2) by means of a structure-based de novo design with the two known inhibitor scaffolds that contain a proper chelating group for the active-site Mg2+ ion. Because these newly found inhibitors were screened for having desirable physicochemical properties as a drug candidate and exhibited a moderate inhibitory activity with IC50 values ranging from 6 to 50 mu M, they deserve consideration for further investigation to develop new anticancer medicines. Structural features relevant to the stabilization of the identified inhibitors in the active site of Eya2 phosphatase are discussed in detail. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.title | Structure-based de novo design of Eya2 phosphatase inhibitors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ryu, Seong Eon | - |
dc.identifier.doi | 10.1016/j.jmgm.2012.05.003 | - |
dc.identifier.scopusid | 2-s2.0-84867458442 | - |
dc.identifier.wosid | 000313392800041 | - |
dc.identifier.bibliographicCitation | JOURNAL OF MOLECULAR GRAPHICS & MODELLING, v.38, pp.382 - 388 | - |
dc.relation.isPartOf | JOURNAL OF MOLECULAR GRAPHICS & MODELLING | - |
dc.citation.title | JOURNAL OF MOLECULAR GRAPHICS & MODELLING | - |
dc.citation.volume | 38 | - |
dc.citation.startPage | 382 | - |
dc.citation.endPage | 388 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Computer Science | - |
dc.relation.journalResearchArea | Crystallography | - |
dc.relation.journalResearchArea | Mathematical & Computational Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Computer Science, Interdisciplinary Applications | - |
dc.relation.journalWebOfScienceCategory | Crystallography | - |
dc.relation.journalWebOfScienceCategory | Mathematical & Computational Biology | - |
dc.subject.keywordPlus | PROTEIN-TYROSINE PHOSPHATASES | - |
dc.subject.keywordPlus | EYES ABSENT | - |
dc.subject.keywordPlus | GENETIC ALGORITHM | - |
dc.subject.keywordPlus | DISCOVERY | - |
dc.subject.keywordPlus | SOLVATION | - |
dc.subject.keywordPlus | DOCKING | - |
dc.subject.keywordAuthor | De novo design | - |
dc.subject.keywordAuthor | Eya2 phosphatase | - |
dc.subject.keywordAuthor | Inhibitor | - |
dc.subject.keywordAuthor | Chelating group | - |
dc.subject.keywordAuthor | Anticancer agents | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1093326312000551?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.